Search Medical Condition
Please enter condition
Please choose location from dropdown

L'Hospitalet de Llobregat, Spain Clinical Trials

A listing of L'Hospitalet de Llobregat, Spain clinical trials actively recruiting patients volunteers.

RESULTS

Found (1043) clinical trials

Parenteral Antibiotics Compared to Combination of Oral and Parenteral Antibiotics in Colorectal Surgery Prophylaxis

Routine antibiotics for the intravenous and oral prophylaxis of colorectal surgery will be used. Experimental group: Patients undergoing elective colorectal surgery that involves, colonic resection. The antibiotic prophylaxis in this group will be composed of: An oral antibiotic pattern of ciprofloxacin (750mg / 12h, 2 doses) and metronidazole (250mg / ...

Phase

0.0 miles

Learn More »

Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)

The primary objective of this study is to evaluate the efficacy of letermovir (LET) versus valganciclovir (VGCV) in preventing CMV disease in adult kidney transplant recipients. The primary hypotheses are that LET is non-inferior to VGCV; and if non-inferiority is demonstrated, that LET is superior to VGCV, in preventing CMV ...

Phase

0.0 miles

Learn More »

Thromboelastometry in Liver Transplantation

Thromboelastometry better assess coagulation than standard coagulation test in patients undergoing ortothopic liver transplantation. In a post-hoc analysis from a randomized study recently conducted by our group, presurgical values of MA10 Extem < 35 mm are highly predictive of RBC administration , with no further improvement over MA10 Extem >40 ...

Phase N/A

0.0 miles

Learn More »

OPTImization of the Dose of tacroliMUS by Bayesian Prediction

The results of the study of genetic polymorphisms performed in renal transplant patients at our hospital demonstrated the influence of CYP3A5 * 3 and CYP3A4 * 22 single nucleotide polymorphism (SNPs) on exposure to Tac. From these results, the first population pharmacokinetic model was developed, which included CYP3A5 * 3 ...

Phase

0.0 miles

Learn More »

Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma

The primary objective of this study is to assess the overall safety profile of idelalisib monotherapy in patients with refractory follicular lymphoma (FL).

Phase N/A

0.0 miles

Learn More »

Atezolizumab Trial in Endometrial Cancer - AtTEnd

Atezolizumab is an engineered humanised monoclonal immunoglobulin G1 antibody that binds selectively to PD-L1 and prevents its interaction with PD-1 and B7-1. In May 2016 atezolizumab was approved by the FDA for patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following any platinum-containing chemotherapy, ...

Phase

0.0 miles

Learn More »

Pembrolizumab in Combination With Doxorubicin in Advanced Recurrent or Metastatic Endometrial Cancer

This is a non-randomized, single arm, multi-center, phase II study of pembrolizumab in combination with doxorubicin in subjects with recurrent/metastatic endometrial cancer.

Phase

0.0 miles

Learn More »

REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia

Phase I-II multi-site, exploratory, interventional, unmasked, non-randomized, single arm clinical trial. A single drug will be administered in four different, increasing doses to four consecutive cohorts. The first phase of the study will focus on determining the most effective and tolerated dose of the study drug. The second phase will ...

Phase

0.0 miles

Learn More »

AEDV Registry of Primary Cutaneous Lymphoma

Registry of patients with Primary Cutaneous Lymphoma seen at participating centers in Spain. The registry will identify patients with this disease and includes information about stage, diagnostic and therapeutic interventions and willingness to participate in further studies. Data is entered in the registry in each of the participating cutaneous lymphoma ...

Phase N/A

0.0 miles

Learn More »

SELIBORDARA: Selinexor Bortezomib and Daratumumab in Multiple Myeloma

This is a Phase 2, single-arm, open, non-randomized, multicenter study of the SINE compound selinexor plus low-dose dexamethasone, in combination with bortezomib and daratumumab. Sixty-two patients with R/R MM who meet eligibility criteria and have none of the exclusion criteria will be enrolled to receive SVDd until either disease progression ...

Phase

0.0 miles

Learn More »